- Active not recruitingPHASE1, PHASE2
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
This study looks at new drug combinations for advanced cancers. We want to see if they're safe, how well they work, and what effects they have on the body. It involves different stages to find the best doses and see benefits.
For: Advanced Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
This study looks at new drug combinations before and after surgery for early-stage lung cancer. It aims to see if these treatments are safe and work well to help people with non-small cell lung cancer.
For: Non-small Cell Lung CancerUnited States · Belgium · Canada - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
For: Non-Small Cell Lung CancerUnited States · Australia · Brazil - Active not recruitingPHASE3
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
This study looks at a new drug, Monalizumab, combined with Cetuximab, for people with head and neck cancer that has come back or spread. It compares this combination to Cetuximab with a dummy drug (placebo) to see if it's safe and effective.
For: Squamous Cell Carcinoma of the Head and NeckUnited States · Argentina · Australia